Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NMTRNASDAQ:RDHLNASDAQ:TTNPNASDAQ:VIVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNMTR9 Meters Biopharma$0.00$0.07▼$6.56$1.04M1.36315,915 shsN/ARDHLRedhill Biopharma$1.90+3.3%$1.99$1.71▼$20.28$4.35M4.22164,301 shs22,426 shsTTNPTitan Pharmaceuticals$4.26-1.8%$4.30$3.03▼$14.80$3.89M1.3139,008 shs13,142 shsVIVSVivoSim Labs$1.46+3.5%$0.00$1.41▼$21.96$3.80M1.0358,209 shs41,915 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNMTR9 Meters Biopharma0.00%0.00%0.00%0.00%+6,463.64%RDHLRedhill Biopharma0.00%+8.57%+2.70%-36.45%-99.23%TTNPTitan Pharmaceuticals0.00%-3.20%-7.19%+1.67%-38.97%VIVSVivoSim Labs0.00%-9.32%+145,999,900.00%+145,999,900.00%+145,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNMTR9 Meters BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ARDHLRedhill BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ATTNPTitan PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AVIVSVivoSim LabsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNMTR9 Meters Biopharma 0.00N/AN/AN/ARDHLRedhill Biopharma 0.00N/AN/AN/ATTNPTitan Pharmaceuticals 0.00N/AN/AN/AVIVSVivoSim Labs 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNMTR9 Meters BiopharmaN/AN/AN/AN/A$0.19 per shareN/ARDHLRedhill Biopharma$8.04M0.54N/AN/A($3.66) per share-0.52TTNPTitan Pharmaceuticals$180K21.54N/AN/A$2.67 per share1.60VIVSVivoSim Labs$140K27.11N/AN/A$5.54 per share0.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNMTR9 Meters Biopharma-$43.77M-$3.46N/AN/AN/AN/A-584.97%-159.45%N/ARDHLRedhill Biopharma-$8.27MN/A0.00∞N/AN/AN/AN/AN/ATTNPTitan Pharmaceuticals-$4.71M-$4.59N/A∞N/AN/A-145.92%-129.20%8/13/2025 (Estimated)VIVSVivoSim Labs-$2.48M-$10.20N/A∞N/A-1,725.00%-46.87%-28.62%N/ALatest NMTR, RDHL, VIVS, and TTNP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025TTNPTitan PharmaceuticalsN/A-$0.62N/A-$0.62N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNMTR9 Meters BiopharmaN/AN/AN/AN/AN/ARDHLRedhill BiopharmaN/AN/AN/AN/AN/ATTNPTitan PharmaceuticalsN/AN/AN/AN/AN/AVIVSVivoSim LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNMTR9 Meters BiopharmaN/A0.590.59RDHLRedhill BiopharmaN/A0.540.37TTNPTitan PharmaceuticalsN/A7.737.73VIVSVivoSim LabsN/A3.253.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNMTR9 Meters Biopharma22.34%RDHLRedhill Biopharma7.20%TTNPTitan Pharmaceuticals31.49%VIVSVivoSim Labs8.23%Insider OwnershipCompanyInsider OwnershipNMTR9 Meters Biopharma2.40%RDHLRedhill Biopharma6.81%TTNPTitan Pharmaceuticals0.72%VIVSVivoSim Labs3.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNMTR9 Meters Biopharma2014.34 million13.99 millionNo DataRDHLRedhill Biopharma2102.29 million2.14 millionNo DataTTNPTitan Pharmaceuticals10910,000907,000OptionableVIVSVivoSim Labs202.60 million2.50 millionN/ANMTR, RDHL, VIVS, and TTNP HeadlinesRecent News About These CompaniesNo headlines for this company have been tracked by MarketBeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNMTR, RDHL, VIVS, and TTNP Company Descriptions9 Meters Biopharma NASDAQ:NMTR9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.Redhill Biopharma NASDAQ:RDHL$1.90 +0.06 (+3.26%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$1.86 -0.03 (-1.84%) As of 06/20/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.Titan Pharmaceuticals NASDAQ:TTNP$4.26 -0.08 (-1.84%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$4.36 +0.10 (+2.35%) As of 06/20/2025 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.VivoSim Labs NASDAQ:VIVS$1.46 +0.05 (+3.54%) As of 06/20/2025 04:00 PM EasternOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
